

## **HSV-1/2 Seronegativity and HCV Seropositivity in People Living with HIV presenting at a tertiary care Teaching Hospital in Awka, Anambra State, Nigeria**

### **ABSTRACT**

Herpes simplex virus has public health importance as a leading cause of genital ulcers, which also facilitate human immunodeficiency virus while co-infection with hepatitis C virus and human immunodeficiency virus is common in certain populations. This study was carried out with the aim of determining the prevalence of Herpes simplex virus and hepatitis C virus in people living with HIV attending a teaching hospital in Awka, Anambra State, Nigeria. Blood samples were randomly collected from 100 HIV-infected individuals of which 42 were males and 58 were females and analysed using ELISA. Results showed an overall prevalence of HCV to be 4.0% seropositivity and HSV to be 0.0% with 100.0% seronegativity. Higher prevalence of HCV occurred in ages groups 26-35 years (4.7%) than 16-25 years (4.4%) and 36 years & above (4.0%) with a significant difference of  $p < 0.05$ . It showed that HCV antibody was only present among females (6.9%) and target not detected (TND) with 4.4%. Higher prevalence of HCV occurred among HIV-infected individuals having CD4 counts of  $>350$  cells/mm<sup>3</sup> than the  $<200$  cells/mm<sup>3</sup> and 200-249 cells/mm<sup>3</sup> (0.0%). The study showed 4.4% seropositivity of HCV and 100.0% seronegativity of HSV in HIV-infected individuals with the highest prevalence of HCV recorded for age boundary 26-35 years. Thus, the increased number of HCV seropositivity among HIV-infected individuals indicates that there is a synergistic relationship between HIV and HCV infection. This study recommends that more attention should be given to the area of HIV/HCV coinfection in the management of infected patients.

**Keywords:** HCV, HSV, Seronegativity, Seropositivity, PLWHA

### **1. INTRODUCTION**

“Sexually transmitted infections (STIs) are emerging public health concerns”.<sup>1</sup> “Studies have demonstrated the bidirectional relationships between HIV and several STIs, including herpes simplex virus-2 (HSV-2), hepatitis B and C viruses, human papilloma virus, syphilis, gonorrhoea, chlamydia, and trichomonas”.<sup>2</sup> “HIV-1 may affect the clinical presentation, treatment outcome, and progression of STIs, such as syphilis, HSV-2, and hepatitis B and C viruses. Likewise, the presence of an STI may increase both genital and plasma HIV-1 RNA levels, enhancing the transmissibility of HIV-1, with important public health implications”.<sup>2</sup>

“Globally, infections caused by herpes simplex virus types 1 and 2 are amongst the most common human viral infections”.<sup>3</sup> “Herpes simplex virus (HSV) can cause genital ulcers, herpetic whitlow, and corneal blindness”.<sup>4</sup> “The transmission of HSV-2 is mainly through sexual means, while HSV-1 is transmitted non-sexually during infancy”.<sup>3,5</sup> “However, there is an increasing proportion of genital herpes infections

caused by HSV-1 in the developed world”.<sup>3</sup>“This is probably due to changes in sexual behavior, with oral-genital sex becoming very common”.<sup>3,6</sup>“Both types of the virus cause sub-clinical infection and thus many of those infected are oblivious of their infection status”.<sup>3</sup>

“HSV-2 infection is one of the most common sexually transmitted infections (STIs), with the highest burden in Africa”.<sup>1</sup>“Although HSV-1 is most often transmitted through nonsexual contact, recent data from some developed countries indicate that a significant proportion of first-episode genital herpes is caused by HSV-1”.<sup>7</sup>“Genital infection with herpes simplex virus type 2 (HSV-2) facilitates the acquisition of HIV, both mutually reinforcing infection”.<sup>8</sup>“In fact, HIV percutaneous transmission is substantially facilitated by the co-existing STI.<sup>1</sup> Prevalent STIs, particularly HSV-2 are established risk factors for HIV acquisition and transmission”.<sup>1</sup>

“Co-infection with hepatitis C virus (HCV) and HIV is common in certain populations”.<sup>9</sup>“Around 130 million infections of HCV with 3% overall prevalence are there worldwide.<sup>10</sup> There are approximately 4–5 million persons coinfecting with HIV”.<sup>10</sup>According to Austin et al.<sup>11</sup>, “HCV is a leading cause of both acute and chronic hepatitis worldwide”. “While HCV seropositivity rates for voluntary blood donor populations are typically less than 1%, HCV antibody prevalences ranging from 10 to 90% have been recorded in hemodialysis patients, intravenous drug abusers, and individuals with various liver disorders”.<sup>11</sup>

“Several studies have shown that there are higher levels of HCV in the blood of HIV-infected patients coinfecting with the HCV following a rapid progression to liver diseases related to the HCV and a higher risk of liver disease and cirrhosis. HCV is now considered an adaptable infection in HIV-infected people although it is not regarded as an HIV-defining illness. A 2017 systematic review and meta-analysis of 55 prospective studies reported that the risk of HIV acquisition was almost tripled in the presence of established (prevalent) HSV and HCV infections and quintupled in the presence of recently acquired (incident) HSV and HCV infections”.<sup>12</sup>“HSV infection is associated with an increased risk of both HIV transmission and acquisition”.<sup>13</sup>

“There is considerable biological and epidemiological evidence that HSV-2 infection facilitates both acquiring and transmitting HIV”.<sup>14</sup> “Although most research on HSV-2 and HIV has been conducted in Africa, several studies indicate positive associations between HSV-2 and HIV in the United States”.<sup>14,15</sup> “Because HSV-2 is transmitted sexually but not through sharing drug injection equipment, it can be used as a biomarker for sexual risk of HIV”.<sup>14,16</sup>According to a Greek study (Panayiotakopoulos et al.), “anti-human herpes virus 8 (HHV-8) positive patients had a tendency to have higher rates of HCV infection”.<sup>17</sup> In HIV-1-positive people, the initial anti-HHV-8 status is not a predictive factor. According to Panayiotakopoulos et al., “a high seroprevalence in people with HEPs may be a reflection of their risk-taking lifestyle”.<sup>17</sup>

Seroepidemiological studies are critical to understanding the pattern and distribution of infection within populations. Based on these facts, the study is therefore, undertaken

to evaluate the prevalence of HSV and HCV among HIV-infected individuals on an anti-retroviral treatment programme in a tertiary care Teaching hospital in Awka, Anambra State, Nigeria.

## **2. MATERIALS AND METHODS**

### **2.1 Study Area**

This study was conducted among people living with HIV attending a tertiary care Teaching Hospital in Awka, Anambra State, Nigeria.

### **2.2 Eligibility Criteria**

Inclusion criteria included all HIV-infected individuals (age above 16 years) presenting at the HIV unit of the hospital. Non-HIV-positive patients and minors (age below 16 years) were excluded from the study.

### **2.3 Study Population**

Plasma samples were randomly collected from 100 HIV-infected individuals of which 42 were females and 58 were males. The samples were collected from the HIV Unit of the tertiary hospital in Anambra State. Samples were collected between November 2020 and March 2022. The study age and class boundary were between 16-25, 26-35, 36-45 and 46-55 years.

### **2.4 Sample Collection and Preparation**

Five millilitres (5ml) of blood from each patient were aseptically collected during routine investigations so that the participants were not bled twice. The samples were collected into sterile EDTA bottles and plasma samples were obtained after centrifugation. Samples were appropriately labelled and stored in two aliquots at  $-20^{\circ}\text{C}$  and  $-80^{\circ}\text{C}$  until analysis.

### **2.5 Serological analysis**

The HIV status was reconfirmed by screening their blood samples for the reality of HIV-1, 2, O and P24 HIV-1 antibodies, using Alere Determine test strips (Alere, Japan) and ELISA (factory-made by DIA.PRO Diagnostic Bioprobes Srl, Milano – Italy). Blood samples drawn from participating HIV-infected individuals were assayed for Antibodies against HCV and anti-HSV-IgG and anti-HSV-IgM using enzyme-linked immunosorbent assay (ELISA by Dia. Pro, Italy), according to manufacturer instructions. HCV infection was considered to be present in subjects who tested positive for anti-HCV. The interpretation of test results was performed according to the manufacturer's specifications.

### **2.6 CD4 T cell count enumeration**

EDTA-treated blood samples were used for CD4 T cell count using Partec CyFlow<sup>®</sup> Counter (Partec GmbH, Germany), following the instruction of the manufacturer. The

specimens were analyzed on a flow cytometer for the detection of cell surface markers for CD4 cells. Results were classified based on the CDC (1997) guidelines

## 2.7 Data Analysis

Statistical evaluation of the data was tabulated and the total percentage (%) of HCV and HSV prevalence was calculated based on each age boundary using SPSS. Calculated percentage prevalence was recorded accordingly, the result was determined and a conclusion was drawn.

## 3. RESULT

Results showed an overall prevalence of HCV to be 4.0% seropositivity and HSV to be 0.0% with 100.0% seronegativity. Results of the prevalence of HCV and HSV in HIV-infected patients, Viral load and CD4 counts are presented in Table 1. Results of the present study show that the prevalence of HCV of 4.4% (16-25 years), 4.7% (26-35 years) and 4.0% (36 years & above) with a significant difference of  $p < 0.05$ . It showed that HCV antibody was only present among females (6.9%) and target not detected (TND) with 4.4%. Higher prevalence of HCV occurred among HIV-infected individuals having CD4 counts of  $>350$  cells/mm<sup>3</sup> than the  $<200$  cells/mm<sup>3</sup> and 200-249 cells/mm<sup>3</sup> (0.0%) as shown in Table 1.

**Table 1: Prevalence of HCV in HIV-infected patients**

Variables	No. Tested	No. Positive for HCV (%)
<b>Age Group (years)</b>		
16 – 25	23	1(4.3)
26 – 35	43	2(4.7)
36 & above	34	1(2.9)
<b>Sex</b>		
Males	42	0(0.0)
Females	58	4 (6.9)
<b>Viral Load (copies/ml)</b>		
TND	90	4(4.4)
< 40 and above	10	0(0.0)
<b>CD 4 Count (cell/mm<sup>3</sup>)</b>		
<200	18	1(1.5)
200 - 349	20	0(0.0)
$\geq 350$	62	3(4.8)
<b>Total</b>	<b>100</b>	<b>4(4.0)</b>

## 4. DISCUSSION

Herpes simplex virus type 2 (HSV-2) is a public health concern, particularly in developing countries, linked to an increased risk of HIV infection and

transmission.<sup>18</sup> Defining the Prevalence level of HIV/HCV/HSV coinfections becomes pertinent, especially among groups at high risk of the infection. Multiple infections with HCV/HSV significantly exacerbated morbidity in HIV patients. In this study, zero prevalence was reported for HIV/HSV coinfections showing 100.0% seronegativity rate among HIV-infected individuals in Awka, Anambra State, Nigeria. The zero seroprevalence of HSV-2 IgM reported in this study similar to that of Alubi et al. who reported 0.0% for HIV/HSV coinfections in Port Harcourt, Nigeria.<sup>19</sup> Similar to the previous study in other different countries such as Egypt, Saudi Arabia, Brazil and Turkey.<sup>20-23</sup>

This 0.0% reported here for HSV-1 and -2 IgG and IgM antibodies is lower than the 2.8% reported by Okonko et al. in Port Harcourt, Nigeria,<sup>24</sup> the 6.1% reported by Muhammad et al. in Northern Nigeria<sup>18</sup> and the 51.1% and 2.2% reported respectively, for IgG and IgM by Okonko et al. in Port Harcourt, Nigeria.<sup>25,26</sup> However, it is significantly lower than the results obtained by Nag et al. among HIV/HSV-2 coinfecting individuals (34.6%) in Eastern India,<sup>27</sup> 46.1% by Hayatudeen et al. in apparently healthy individuals in Nigeria,<sup>28</sup> the 20.4% by Salman et al. among children under the age of five years (20.4%) in Iraq<sup>29</sup> and the 99.4% in a study conducted in Port Harcourt, Nigeria.<sup>30</sup>

The 100.0% seronegativity reported here corroborated that of Alubi et al. who reported 100.0% seronegativity rate reported for HIV/HSV coinfections in Port Harcourt, Nigeria.<sup>19</sup> This seronegativity rate is substantially higher than the 48.9% reported by Okonko et al. and the 0.6% reported by Okonko and Cookey, both in Port Harcourt, Nigeria.<sup>25,30</sup> However, it is slightly higher than the 97.8% reported by Okonko et al. in a similar study.<sup>24,26</sup>

A previous study in Nigeria by Irena et al. reported a prevalence of HCV coinfections.<sup>31</sup> This result is in support of similar studies carried out by Lacazari et al., (2017) who revealed that the highest number of tested HIV-positive patients was recorded in the same age boundary (26-35 years) and revealed that this age boundary is dominated by sexually active youth.<sup>32</sup>

This study reported a 4.0% prevalence of HCV and this agrees favourably with that of Elenwo et al. in selected areas of Rivers State, Nigeria<sup>33</sup> and that of Okonko and Ernest Nwagwu in another part of Rivers State, Nigeria.<sup>34</sup> It is comparable to 4.3% reported by Ugwu et al. in Anambra State, Nigeria.<sup>35</sup> This is higher than the 0.0% reported by Alli et al. in Ibadan, Nigeria<sup>36</sup>, Okonko et al.<sup>37,38</sup> and Cookey et al.<sup>39</sup> in Port Harcourt, Nigeria, 0.4% reported in Ilorin, Nigeria<sup>40</sup>, 0.5% in Ibadan<sup>41</sup>, 1.3% in Onitsha, Anambra State<sup>42</sup>, 1.0% in Port Harcourt<sup>43</sup> and 2.0% reported among children in Ibadan<sup>44</sup>. However, Okonko et al.<sup>41</sup> found no HIV-HCV coinfections in their study. The 4.0% reported here is below 23.5% reported in Abeokuta, Nigeria<sup>45,46</sup>, the 22.5% in Port Harcourt<sup>47</sup>, the 15.0% reported in Ughelli, Delta State, Nigeria<sup>48</sup>, 11.7% among hospitalized US veterans<sup>11</sup> and 5.6% in Emohua LGA, Rivers State, Nigeria<sup>34</sup>. In a research done in the USA and Europe, patients who were coinfecting with HIV and HCV had a prevalence ranging from 25.0% to 50.0%.<sup>10,49-50</sup> In a different study, 74.0%

of HIV-positive people had HCV.<sup>10,51</sup> According to a study done in Iran, 68.0% of patients had both HIV and HCV coinfection.<sup>10,52</sup> A comparable study with 620 HIV-positive individuals in northern India found that 1.6% of HIV-positive patients also had HCV.<sup>10,53</sup> These prevalence studies were typically conducted in many regions of the world, therefore variations in the prevalence might be attributed to the kinds of risk groups, variations in geographic locations, and variations in the methods of exposure.<sup>10, 54-56</sup>

In similar studies carried out by Mertz et al., older age was not found to be a risk factor for hepatitis C virus infection as it has been previously described.<sup>57</sup> Those who were 30 years or younger had the highest prevalence of HCV antibody but age was not statistically significant. Males had a higher rate of HCV infection in their study but gender was not a significant risk factor in the study by Mertz et al.<sup>57</sup> This study found higher prevalence of HCV among age group 26-35 years. This similar to the observation of Ogbodo et al. who reported higher prevalence in age group 26 years and above in Ughelli, Delta State, Nigeria.<sup>48</sup> Abeni et al. reported higher prevalence in age group 20-30 years in Port Harcourt, Nigeria.<sup>58</sup> Ugwu et al. reported higher prevalence among ages 31 and 40 years.<sup>35,42</sup> Udeze et al. reported higher prevalence of HCV among age groups group below 40 years.<sup>59</sup> Okonko et al. reported prevalence of HCV among age groups group below 30 years in Abeokuta, Nigeria.<sup>60</sup> Elenwo et al. reported higher prevalence in ages 21-40 years.<sup>33</sup> However, Sule et al. reported higher prevalence of HCV among age groups  $\geq 50$  years.<sup>61</sup> Okonko et al. reported higher prevalence in 40 years and above.<sup>41,47,62</sup> Other studies by Okonko and Shaibu<sup>63</sup> and Okonko and Ernest Nwagwu<sup>34</sup> reported higher prevalence in  $\leq 40$  years and  $< 41$  years, respectively. Ogbu-Richard et al. reported higher prevalence in age group 35-44 years in Abeokuta, Nigeria.<sup>46</sup> Ojo et al. reported higher HCV prevalence in 55 years and above.<sup>45</sup> Also, Udeze et al. reported higher prevalence of HCV among age groups group above 20 years in Ilorin, Nigeria<sup>64</sup> while in 2015, Udeze et al. reported higher prevalence of HCV among age groups group  $\leq 20$  years in Ilorin, Nigeria.<sup>40</sup>

In this study, HCV antibody was found only in females. This observation agrees favourably with previous studies in Nigeria. Ugwu et al. reported HCV prevalence only among women in Onitsha, Anambra State, Nigeria.<sup>42</sup> Sule et al. reported higher prevalence of HCV among females than males.<sup>61</sup> Also, Udeze et al.<sup>64</sup> and Okonko et al.<sup>62</sup> reported higher prevalence of HCV among females than males in Ilorin and Ibadan, respectively. Ogbodo et al. reported higher prevalence in females than in males in Ughelli, Delta State, Nigeria.<sup>48</sup> Okonko et al. also reported higher prevalence in females than males in Port Harcourt, Nigeria.<sup>47</sup> Okonko and Ernest Nwagwu also reported higher prevalence in females than males.<sup>34</sup> However, other studies reported somewhat different in Nigeria. Udeze et al. reported higher prevalence of HCV among males than females in Ibadan.<sup>59</sup> Okonko et al. reported prevalence of HCV only in males in Abeokuta and Ibadan, respectively.<sup>41,60</sup> Also in Ibadan, Nigeria, higher prevalence of HCV was reported in male children than in female children.<sup>44</sup> Ojo et al. reported a higher prevalence in males than females in Abeokuta, Nigeria.<sup>45</sup> Udeze et al. reported higher in males in Ilorin, Nigeria.<sup>40</sup> Ogbu-Richard et al. reported higher prevalence in males than females in Abeokuta, Nigeria.<sup>46</sup> Abeni et al. also reported

higher prevalence in males than females in Port Harcourt, Nigeria.<sup>58</sup> Also, Elenwo et al.<sup>33</sup> as well as Okonko and Shaibu<sup>63</sup> reported higher prevalence in males.

Higher seropositivity of HCV occurred among HIV-infected individuals with CD4 cell counts 350 cells/ml than other categories. This observation corroborated that of Elenwo et al., Ugwu et al. and Okonko and Shaibu who reported higher prevalence in individuals with CD4 cell count 350-499 cells/ $\mu$ l.<sup>33,35,42,63</sup> This observation also deviated from the observation of Ogwu-Richard et al. in Abeokuta, Nigeria.<sup>46</sup> According to certain research, persons living with HIV have greater HCV-RNA levels when their CD4 counts are below 200/mm<sup>3</sup>, in contrast to those who have higher CD4 counts.<sup>10,65</sup>

Most studies show a correlation between HIV infection and increased risk of end-stage liver disease, greater HCV viral levels, and persistent hepatitis B virus. Following co-infection with HIV, HCV-RNA levels rise.<sup>10,65</sup> Also, HCV antibody was found only in individuals with target not detected (TND) viral load. This result agrees with Ugwu et al. in related studies.<sup>35,42</sup> This is a deviation from Okonko and Shaibu who reported higher prevalence among individuals with viral load  $\geq 10,000$  copies/ml in Yenagoa, Bayelsa State, Nigeria.<sup>63</sup>

Regarding the effect of STIs on HIV-1 progression, the most studied interrelationship has been with HIV-1/HSV-2 coinfection, with recent studies showing that antiherpetic medications slow the time to CD4  $< 200$  cells/mm<sup>3</sup> and antiretroviral therapy among coinfecting patients.<sup>2</sup> The impact of other chronic STIs (hepatitis B and C) on HIV-1 progression requires further study, but some studies have shown increased mortality rates.<sup>2</sup> According to a meta-analysis, patients who had both HIV and HCV coinfection were three times more likely than those who just had HCV infection to proceed to cirrhosis or decompensated liver disease.<sup>66,67</sup> Patients with low CD4 T lymphocyte cell counts who also have HIV coinfection are even more at risk of progression.<sup>67</sup> Antiretroviral therapy (ART) appears to slow the rate at which HCV disease progresses in patients who also have HIV, but multiple studies have shown that this rate still surpasses that of patients who do not have HIV.<sup>67-69</sup>

## 5. CONCLUSION

The study showed 4.4% seropositivity of HCV and 100.0% seronegativity of HSV in HIV-infected individuals with the highest prevalence of HCV recorded for age boundary 26-35 years. Thus, the study found that HCV was more common in HIV-infected than HSV in HIV-infected individuals. The increased number of HCV seropositivity among HIV-infected individuals indicates that there is a synergistic relationship between HIV and HCV infection. This study recommends that more attention should be given to the area of HIV/HCV coinfection in the management of infected patients.

Ethical Approval and Consent

Written consent of each participant was obtained before sample collection and the study was approved by the Research Ethics Committee of the Chukwuemeka Odimegwu Ojukwu University Teaching Hospital (COOUTH) in Awka, Anambra State, Nigeria.

## REFERENCES

1. Ouedraogo, H. G., Zida, S., Sagna, T., Zoure, A. A., Compaore, R. T., Soubeiga, S. T., Ouedraogo, O., Kambiré, D., Belemsaga/Yugbaré, D., Cissé, K., Traoré, Y., Barro, N., & Kouanda, S. (2023). Herpes simplex virus type 2 (HSV-2) and its association with HIV, HCV, HBV, HTLV-1&2 and syphilis among men who have sex with men in Burkina Faso. *Indian journal of medical microbiology*, 42, 59–64. <https://doi.org/10.1016/j.ijmmb.2022.09.007>
2. Chun, H. M., Carpenter, R. J., Macalino, G. E., & Crum-Cianflone, N. F. (2013). The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature. *Journal of sexually transmitted diseases*, 2013, 176459. <https://doi.org/10.1155/2013/176459>
3. Reward, E. E., Muo, S. O., Orabueze, I. N. A., & Ike, A. C. (2019). Seroprevalence of herpes simplex virus types 1 and 2 in Nigeria: a systematic review and meta-analyses. *Pathogens and global health*, 113(5), 229–237. <https://doi.org/10.1080/20477724.2019.1678938>
4. Birch, S., Audsley J, Cros P, Goodman Z, McLean C, Mijch A, & Lewin SR, (2019). HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection. *Journal of Medical Virology*.; 84:993–1001.
5. Malary, M., Abedi, G., Hamzehgardeshi, Z., Afshari, M., & Moosazadeh, M. (2016). The prevalence of herpes simplex virus type 1 and 2 infection in Iran: A meta-analysis. *International journal of reproductive biomedicine*, 14(10), 615–624.
6. Malkin JE. Epidemiology of genital herpes simplex virus infection in developed countries. *Herpes*. 2004;11(Supp\_1):S2A–23A.
7. Pue, B. & Benet, K. (2019). Management and treatment of chronic hepatitis C in HIV patients. *Semin Liver Dis.*; 32:138–46.
8. Anaedobe CG, Ajani TA. Sexual behavioural correlates of herpes simplex virus type 2 infections among pregnant women in South-western Nigeria. *Inter J Com Med Pub Health*. 2018;5:1274–1280.
9. Maier, I., & Wu, G. Y. (2002). Hepatitis C and HIV co-infection: a review. *World journal of gastroenterology*, 8(4), 577–579. <https://doi.org/10.3748/wjg.v8.i4.577>
10. Akhtar, A., Fatima, S., Saeed, H., Soo, C. T., & Khan, A. H. (2022). HIV-HCV Coinfection: Prevalence and Treatment Outcomes in Malaysia. *Intervirology*, 65(2), 87–93. <https://doi.org/10.1159/000518836>
11. Austin, G. E., Jensen, B., Leete, J., De L'Aune, W., Bhatnagar, J., Racine, M., & Braun, J. E. (2000). Prevalence of hepatitis C virus seropositivity among hospitalized US veterans. *The American Journal of the Medical Sciences*, 319(6), 353–359. <https://doi.org/10.1097/00000441-200006000-00002>
12. Rosenthal, M., Castilho MC, Santos ICV, Moura MAS, & Segurado AC. (2019). Low prevalence of hepatitis B virus, hepatitis D virus and hepatitis C virus among patients with human immunodeficiency virus or acquired immunodeficiency syndrome in the Brazilian Amazon basin. *Rev Soc Bras Med Trop.*; 39:519–22.

13. Munawwar, A., Gupta, S., Sharma, S. K., & Singh, S. (2018). Seroprevalence of HSV-1 and 2 in HIV-infected males with and without GUD: Study from a tertiary care setting of India. *Journal of laboratory physicians*, 10(3), 326–331. [https://doi.org/10.4103/JLP.JLP\\_7\\_18](https://doi.org/10.4103/JLP.JLP_7_18)
14. Des Jarlais, D. C., Arasteh, K., McKnight, C., Hagan, H., Perlman, D. C., & Semaan, S. (2011). Associations between herpes simplex virus type 2 and HCV With HIV among injecting drug users in New York City: the current importance of sexual transmission of HIV. *American journal of public health*, 101(7), 1277–1283. <https://doi.org/10.2105/AJPH.2011.300130>
15. Des Jarlais D, Semaan S. HIV and other sexually transmitted infections in injection drug users and crack cocaine smokers. : Holmes K, Sparling P, Stamm W, Piot P, *Sexually Transmitted Diseases*. New York: McGraw Hill; 2008:237–255
16. Des Jarlais D, Arasteh K, McKnight C, Hagan H, Perlman D, Friedman S. Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. *Drug Alcohol Depend*. 2009;101(1–2):88–91
17. Panayiotakopoulos, G. D., Mavroyianni, D., Politou, M., Aroni, K., Kosmopoulou, O., Kontos, A.N., Choremi-Papadopoulou, H., Pediaditis, J. & Kordossis, T. (2005). Human Herpesvirus-8 Seropositivity and Clinical Correlations in HIV-1–Positive and Highly Exposed, Persistently HIV-Seronegative Individuals in Greece. *AIDS Patient Care & STDs*, 19(6), 375-383.
18. Muhammad, I.A., Hafiz, T.R., Muhammad, F., & Rogo, L.D. (2021). Seroprevalence and Risk Factors of Herpes Simplex Virus Type-2 (HSV-2) Infection among HIV-Positive Patients in a Selected Teaching Hospital in Northern Nigeria. *OIRT Journal of Medical and Health Sciences*,1(2), 51-55. Doi: <https://dx.doi.org/10.53944/ojmhs-2113>
19. Alubi, P. C., Okonko, B. J., Ogbuji, C. C., Mbah, E. I. & Okonko, I. O. (2023). Serological Prevalence of Herpes Simplex Virus, Syphilis, and *H. pylori* Coinfections amongst HIV-Infected Individuals Receiving Care in a Secondary Healthcare Facility in Port Harcourt, Nigeria. *Journal of Multidisciplinary Research Updates (IJMRU)*, 05(02):001-016
20. Gomaa, H.H.A., S.A.S. Hasan, N. Harb, A.H.A. Gomaa and M. Anani. 2022. Prevalence of *Herpes simplex* virus in pregnant women in Ismailia city. *Journal of Virological Sciences*, 10(1): 18-26.
21. Al-Hakami, A.M., Paul, E., Al-Abad, F., Alzoani, A.A., Shati, A.A., Assiri, M.I. and Chandramoorthy, H.C. 2020. Prevalence of toxoplasmosis, rubella, cytomegalovirus, and herpes (TORCH) infections among women attending the antenatal care clinic, maternity hospital in Abha, Southwestern Saudi Arabia. *Saudi Med. J.*, 41(7): 757. <https://doi.org/10.15537/smj.2020.7.25121>
22. Lima, L.R., Dos-Santos, P.J.D.S., De Almeida, N.A., De Meneses, M.D., Aguiar, S.F., Fernandes, C.A., and de Paula, V.S. 2021. Seroprevalence of human alphaherpesvirus 1 and 2 among pregnant women infected or uninfected with Zika virus from Rio de Janeiro, Brazil. *J. Med. Virol.*, 93(6): 3383-3388. <https://doi.org/10.1002/jmv.26665>
23. Duran, N., 2004. Serological evaluation of HSV-1 and HSV-2 infection in pregnancy. *Turkish J. Med. Sci.*, 34(2): 97-101.

24. Okonko, I.O., Cooney, T. I., Okerentugba, P. O. & Frank-Peterside, N. (2015). Serum HSV-1 and -2 IgM in Pregnant Women in Port Harcourt, Nigeria, *Journal of Immunoassay and Immunochemistry*, 36(4): 343-358
25. Okonko, I. O., Benjamin, A. F., Cooney, T. I., Okonko, B. J. & Innocent-Adiele, H. C. (2023a). Prevalence of Herpes Simplex Virus Type-2 IgG Antibody among pregnant women in Port-Harcourt, Nigeria. *Microbiologia Medica* 2023; 38 (1):10829, 6-10.
26. Okonko I. O., Awah A., Omang P. A., Cooney T. I., Okonko, B. J., Onu E. N., Oketah, E. N., Innocent-Adiele H. C., Adim C. C., & Amadi, B. O. (2023b). Serological Evidence of Herpes Simplex Virus Type 2 IgM Antibody among Expectant Mothers Attending a Tertiary Healthcare Facility in Port Harcourt, Nigeria. *Asian Journal of Research in Nursing and Health*, 6(1), 442–450.
27. Nag, S., Sarkar, S., Chattopadhyaya, D., Bhattacharya, S., Biswas, R., & SenGupta, M. (2015). Seroprevalence of Herpes Simplex Virus Infection in HIV Coinfected Individuals in Eastern India with Risk Factor Analysis. *Advances in Virology*, 7, 537-539.
28. Hayatudeen, M.R, Mukhtar, G.L., & Aminu, M. (2017). Seroprevalence of Immunoglobulins G and M associated with herpes simplex virus type 2 among apparently healthy individuals in Katsina State, Nigeria. *UMYU Journal of Microbiology Research*, 2(1),186-191.
29. Salman, H.J., Chaloob, F.A., Al-Shuwaik, A.M., & Kadhim, H.S., (2018). Seroprevalence of Herpes Simplex Virus type 2 IgG, IgM antibodies among hospitalized children under 5. years. *Biochemical and Cellular Archives*, 18(1), 161-167.
30. Okonko, I.O. & Cooney, T.I. (2015). Seropositivity and determinants of immunoglobulin-G (IgG) antibodies against Herpes simplex virus (HSV) types - 1 and -2 in pregnant women in Port Harcourt, Nigeria. *Journal of African Health Science*, 15(3), 737-747.
31. Irena Maier & George Y. Wu (2002).Hepatitis C and HIV co-infection. *World J Gastroenterology*, 8 (4): 577–579.
32. Lacazari, K., Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, & Latka MH (2017). Prevalence of hepatitis C virus infection among injection drug users in the United States, *Clin Infect Dis* ; 46:1852–8.
33. Elenwo, M., Oketah, E. N., Okerentugba, P. O. & Okonko, I. O. (2023). Coinfection of HCV among HIV-infected patients: A Cross-Sectional Study in Selected Hospitals in Rivers State, Nigeria. *International Journal of Science and Research Achieve*, 10(1), 758-763
34. Okonko, I. & Ernest Nwagwu, H. (2023). Serological Prevalence of Hepatitis C Virus among Febrile Patients Attending a General Hospital in Emohua LGA, Rivers State, Nigeria. *Preprints* 2023, 2023030094. <https://doi.org/10.20944/preprints202303.0094.v1>.
35. Ugwu, C. H., Oketah, E. N., Okerentugba, P. O., Frank-Peterside, N., & Okonko, I. O. (2023a). Co-infection of HIV/Hepatitis C virus: A cross-sectional study from A University Teaching hospital in Anambra State, Nigeria. *Magna Scientia Advanced Biology and Pharmacy (MSABP)*, 09 (01):001-007

36. Alli, J. A., Okonko, I. O., Abraham, O. A., Kolade, A. F., Ogunjobi, P. I., Tonade, O. O., Ojezele, M. O. & Nwanze, J. C. (2010). A serosurvey of blood parasites (Plasmodium, Microfilaria, HIV, HBsAg, HCV antibodies) in prospective Nigerian blood donors. *Research Journal in Medical Sciences* 4(4):255-275.
37. Okonko, I. O., Ikunga, C. V., Anugweje, K. C. & Okerentugba, P. O. (2014). Anti-hepatitis C virus (HCV) antibody detection among fresh undergraduate students in Port Harcourt, Nigeria. *Basic Sciences of Medicine*, 3(2): 26-29
38. Okonko, I.O., Biragbara, M. T., Cookey, T. I., Okonko, B. J., Adim, C. C.& Innocent-Adiele, H. C. (2023). Serological Evidence of HBV, HCV and HEV Infection Among ART-Naïve HIV-1 Infected Individuals in a Tertiary Health Facility in Port Harcourt, Nigeria, from 2016 – 2017. *American Journal of Multidisciplinary Research and Development (AJMRD)*, 5(04):48-57
39. Cookey, T. I., Okonko, I. O. & Frank-Peterside, N. (2021). Zero Prevalence of HIV and HCV Coinfection in the Highly HIV-infected Population of Rivers State, Nigeria. *Asian Journal of Research in Medical and Pharmaceutical Sciences*, 10(3): 9-16
40. Udeze, A. O., Ali, U. M., Adeoye, P. A., Odugbesi, A. E., Sule, W. F. & Okonko, I. O. (2015). Hepatitis B and C seropositivity in a cohort of HIV-positive patients in Ilorin, North-central Nigeria. *Nigerian Journal of Microbiology*, 28: 2767-2776
41. Okonko, I. O., Anugweje, K. C., Adeniji, F. O. & Abdulyekeen, R. A. (2012c). Syphilis and HIV, HCV and HBsAg coinfections among Sexually Active Adults. *Nature and Science*; 10(1):66-74
42. Ugwu, C. H., Oketah, E. N., Okoli, U. O., Okerentugba, P. O., Frank-Peterside, N., & Okonko, I. O. (2023b). Serological Prevalence of HCV/HIV Co-Infection among HIV-Infected Patients in Onitsha, Anambra State, Nigeria. *International Journal of Multidisciplinary Research and Technology (IJMRT)*, 4(6):74-84
43. Aaron, U. U., Okonko, I. O. & Frank-Peterside, N. (2021). The Prevalence of Hepatitis E, Hepatitis C and Hepatitis B Surface Antigenemias in HAART Experienced People Living with Human Immunodeficiency Virus (HIV) in Rivers State, Nigeria. *Journal of Biomedical Sciences*, 10(S4):001.
44. Okonko, I., Adepoju, A., Okerentugba, P., Nwanze, J. & Onoh, C. (2012a). Detection Of Hepatitis C Virus (HCV) Antibody Among Children in Ibadan, Southwestern Nigeria. *The Internet Journal of Gastroenterology*, Volume 11 Issue 1
45. Ojo DA, Akingbade OA, Okerentugba PO & Okonko IO. 2013. Prevalence of Hepatitis C Virus (HCV) seropositivity in a cohort of people living with HIV and AIDS in Abeokuta, Ogun State, Southwestern Nigeria. *New York Science Journal*; 6(7):19-23.
46. Ogwu-Richard, S. A, Ojo, D. A., Akingbade, O. A. & Okonko, I. O. (2015). Triple Positivity of HBsAg, Anti-HCV antibody, and HIV and their influence on CD4<sup>+</sup>lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria. *African Health Sciences* 15(3):719-727
47. Okonko, I. O., Cookey, T. I. & Innocent-Adiele, H. C. (2022). Dual positivity of HIV and anti-HCV in the highly infected population of Rivers State, Nigeria. *International Journal of Scientific Research Updates*, 04(02), 039–048

48. Ogbodo, E. N., Otue A. & Okonko, I. O. (2015). Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria. *African Health Sciences* 15(3):728-736
49. Dodig, M., & Tavill, A. S. (2001). Hepatitis C and human immunodeficiency virus coinfections. *Journal of Clinical Gastroenterology*, 33(5), 367–374. <https://doi.org/10.1097/00004836-200111000-00005>
50. Department of Veterans Affairs Hepatitis C Resource Center, Yee, H. S., Currie, S. L., Darling, J. M., & Wright, T. L. (2006). Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. *The American Journal of Gastroenterology*, 101(10), 2360–2378. <https://doi.org/10.1111/j.1572-0241.2006.00754.x>
51. Alavi, S. M., & Etemadi, A. (2007). HIV/HBV, HIV/HCV and HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. *Pakistan Journal of Medical Sciences*, 23(4), 510.
52. Ramezani, A., Mohraz, M., & Gachkar, L. (2006). Epidemiologic situation of human immunodeficiency virus (HIV/AIDS patients) in a private clinic in Tehran, Iran. *Archives of Iranian Medicine*, 9(4), 315–318.
53. Tripathi, A. K., Khanna, M., Gupta, N., & Chandra, M. (2007). Low prevalence of hepatitis B virus and hepatitis C virus co-infection in patients with human immunodeficiency virus in Northern India. *The Journal of the Association of Physicians of India*, 55, 429–431.
54. Lesi, O. A., Kehinde, M. O., Oguh, D. N., & Amira, C. O. (2007). Hepatitis B and C virus infection in Nigerian patients with HIV/AIDS. *The Nigerian Postgraduate Medical Journal*, 14(2), 129–133.
55. Alter M. J. (2006). Epidemiology of viral hepatitis and HIV co-infection. *Journal of Hepatology*, 44(1 Suppl), S6–S9. <https://doi.org/10.1016/j.jhep.2005.11.004>
56. Rockstroh, J. K., Mocroft, A., Soriano, V., Tural, C., Losso, M. H., Horban, A., Kirk, O., Phillips, A., Ledergerber, B., Lundgren, J., & EuroSIDA Study Group (2005). Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *The Journal of Infectious Diseases*, 192(6), 992–1002. <https://doi.org/10.1086/432762>
57. Mertz, D., Dan, G., Jimmy, K., & Alter, M.J (2017). Epidemiology of viral hepatitis and HIV co-infection. *J Hepatol.*;44(1) :S6–9.
58. Abeni, B.A., Frank-Peterside, N., Agbagwa, O.E., Adewuyi, S.A., Cookey, T.I. & Okonko, I.O. (2020). Seropositivity of Hepatitis C Virus Among Intending Blood Donors in Rivers State, Nigeria. *Asian Journal of Research and Reports in Gastroenterology* 3(3): 24-31
59. Udeze, A. O., Okonko, I. O., Donbraye, E., Sule, W. F., Fadeyi, A. & Uche, L. N. (2009). Seroprevalence Of Hepatitis C Antibodies Amongst Blood Donors in Ibadan, Southwestern, Nigeria. *World Applied Science Journal*, 7 (8):1023-1028.
60. Okonko, I. O., Soley, F. A., Nwanze, J. C. & Onoh, C. C. (2012b). Detection of HCV antibody among sexually active patients in Abeokuta, Southwestern Nigeria. *International Journal of Chemical and Biochemical Sciences* 1(1): 14-20

61. Sule, W. F., Odama, L. E., Daniel, A. L., Faneye, A. O. & Okonko, I. O. (2009). Prevalence of Anti- Hepatitis C Virus in patients attending Federal Medical Centre (FMC), Lokoja, Kogi State, Nigeria. *World Applied Sciences Journal* 7(3): 371- 377.
62. Okonko, I. O., Oyediji, T. O., Anugweje, K. C., Adeniji, F. O., Alli, J. A. & Abraham, O. A. (2012d). Detection of HCV antibody among intending blood donors. *Nature and Science*, 10(1):53-58
63. Okonko, I. & Shaibu, N. (2023). Evidence of HIV/HCV Coinfection Among People Living With HIV/AIDS Attending Federal Medical Centre, Yenagoa, Nigeria. *medRxiv preprint for Health Sciences. Cold Spring Harbor Laboratory BMJ Yale*, p. 1-19. Doi: <https://doi.org/10.1101/2023.03.08.23286986>
64. Udeze, A. O., Bamidele, R. A., Okonko, I. O. & Sule, W. F. (2011). Hepatitis C Virus (HCV) Antibody Detection among First Year Students of University of Ilorin, Ilorin, Nigeria. *World Journal of Medical Sciences* 6(3):162 – 167.
65. Thomas, D. L. (2005). HIV/HCV coinfection: comorbidity and clinical implications. *Advanced Studies in Medicine*, 5(4 C), S352-S355.
66. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. *Clin Infect Dis*. 2001;33(4):562-569. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11462196>.
67. Clinical Info HIV. 2023. Considerations for Antiretroviral Use in Patients with Coinfection in: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV: Panel's Recommendations Regarding Hepatitis C Virus/HIV Coinfection. <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-hepatitis-c-virus-hcv>. March 23, 2023. Accessed: December 08, 2023.
68. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. *Arch Intern Med*. 2006;166(15):1632-1641. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16908797>.
69. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med*. 2009;360(18):1815-1826. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19339714>.